| HOME >> BIOLOGY >> TECHNOLOGY |
Current Products
CHAPTER FOUR: BIOPHARMACEUTICAL PIPELINES
Overview
Biopharmaceutical Development Outlook
Company R&D Profiles
Abbott
Amgen
Biogen Idec
Bristol-Myers Squibb
Eli Lilly
GlaxoSmithKline
Merck KGaA
Novartis
Novo Nordisk
Pfizer
Roche
CHAPTER FIVE: ISSUES AND TRENDS
Overview of the Industry
The Next Generation of Biologics
Technology for Drug Adherence, Targeted Delivery and Monitoring
Government Incentives for Biologic Development
Biopharmaceutical and Biosimilar Drug Development
Clinical Trial Costs
Orphan Drugs
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity
Aging Population
Healthcare Expenditures Growth
Health Care Reform's Impact on Biopharmaceutical Companies
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
Cancer Drugs in Development 2011
The Impact of Targeted Therapy in Oncology
Genome Sequencing for Personalized Healthcare
The Role of Contract Research Organizations
Global Expansion
CHAPTER SIX: MARKET SUMMARY
Market Overview
Biopharmaceutical Product Analysis
Market Forecast
Geographical Analysis
Competitor Analysis
Company Analysis by Therapeutic Segment
CHAPTER SEVEN: COMPANY PROFILES
Introduction
Abbott Laboratories, Inc
Amgen, Inc.
Biogen Idec
Johnson & Johnson
Merck & Co., Inc.
Merck Serono
Novo Nordisk
Pfizer
Roche/Genentech
Sanofi-Aventis/Genzyme
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Global Biopharmaceutical Treatm
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |